Publications by authors named "F X Parnis"
Article Synopsis
- The clinical trial PROpel investigated the combination of olaparib and abiraterone for treating first-line metastatic castration-resistant prostate cancer (mCRPC) and found it improved progression-free survival (rPFS) compared to a placebo with abiraterone.
- In post hoc analyses, asymptomatic/mildly symptomatic patients experienced a significant rPFS benefit (27.6 months vs. 19.1 months) with the treatment, whereas symptomatic patients showed no meaningful improvement (14.1 vs. 13.8 months).
- The study concluded that olaparib plus abiraterone demonstrates efficacy in asymptomatic/mildly symptomatic mCRPC patients, while results for symptomatic
Background: Indoleamine 2,3- dioxygenase 1 (IDO1) is an immunosuppressive enzyme that has been correlated with shorter disease-specific survival in patients with urothelial carcinoma (UC). IDO1 may counteract the antitumor effects of immune checkpoint inhibitors. Epacadostat is a potent and highly selective inhibitor of IDO1.
View Article and Find Full Text PDFBackground: Indoleamine 2,3-dioxygenase 1 (IDO1) levels correlate with poor outcomes in urothelial carcinoma (UC). IDO1 and programmed death-ligand 1 (PD-L1) are often co-expressed. Epacadostat is a potent and highly selective inhibitor of IDO1.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the effectiveness of adding ipilimumab to nivolumab treatment in patients with advanced, non-clear-cell renal cell carcinoma who showed disease progression on nivolumab alone.
- In a phase 2 trial, patients received nivolumab for up to 12 months, then ipilimumab if their condition worsened; the response rates were relatively low, with notable treatment-related adverse events.
- Despite modest overall effects of nivolumab alone, some participants did respond well, and the combination treatments continued to show some promise in managing the disease.
Background: PROpel met its primary endpoint showing statistically significant improvement in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus abiraterone in patients with first-line metastatic castration-resistant prostate cancer (mCRPC) unselected by homologous recombination repair mutation (HRRm) status, with benefit observed in all prespecified subgroups. Here we report the final prespecified overall survival analysis.
Methods: This was a randomised, double-blind, phase 3 trial done at 126 centres in 17 countries worldwide.